Atrial fibrillation (AF), the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), is capable of producing symptoms that impact quality of life and is associated with risk for embolic stroke. However, the influence of AF on clinical course and outcome in HCM remains incompletely resolved.
A trial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) and is responsible for symptoms that interfere with lifestyle in a substantial proportion of patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] AF is significantly more common in HCM than in the general population [4] [5] [6] 8, [13] [14] [15] and has a higher risk for stroke. [16] [17] [18] [19] [20] [21] AF in HCM has been regarded as a progressive arrhythmia responsible for a major impact on clinical course. 6, 7, 15, [21] [22] [23] [24] However, despite its frequency in HCM, the long-term clinical consequences of AF as a determinant of heart failure morbidity as well as disease-related mortality have been incompletely characterized, an issue particularly relevant in the current contemporary treatment era for this disease. Therefore, we believe it is timely to assess individual and group data from our large and longitudinally assessed HCM cohort to determine the natural history, effect of treatment interventions, and outcome in those patients with AF.
METHODS

Patient Selection
The database of patients in the Tufts Medical Center HCM Institute, from 2004 to 2014, was accessed; 1558 consecutive patients had been referred to establish diagnosis or for targeted subspecialty evaluations, and therapy.
Among these 1558 patients, 310 (20%) were identified with ≥1 clinically overt AF episode, documented by ECG, requiring medical attention and consideration for treatment to restore sinus rhythm. Asymptomatic (silent) AF episodes identified fortuitously and solely by interrogation of implantable defibrillator memory, Holter ECG, or other ambulatory monitoring were excluded from this study, 25 as were AF episodes occurring in the first 3 months after myectomy. 10, 11 Most recent clinical status was established by hospital visit or telephone contact. Six patients were lost to followup immediately after the first visit (including 2 internationally), and thereby the final study population comprised 304 patients. Duration of follow-up was 4.8±3.4 years and up to 12 years from study entry (initial evaluation) to most recent contact (or death).
For the purpose of comparison, the 304 study patients with HCM and a history of AF were matched on the basis of sex and age at initial evaluation (±1 year) to a consecutive group of 304 patients with HCM from the same cohort without a history of symptomatic AF. After 1-to-1 matching, mean ages for both groups did not differ significantly (P=0.99).
This study was reviewed and approved by the Institutional Review Board at Tufts Medical Center, allowing retrospective review of medical records, and granted a waiver of informed consent in accordance with 45 CFR 46.116 (d) . All authors had full access to data, take responsibility for the integrity of the data, and have agreed to the paper as written.
Definitions
HCM
The clinical diagnosis of HCM was based on an echocardiographic or cardiovascular magnetic resonance demonstration of a hypertrophied and nondilated left ventricle (LV) with wall thickness ≥13 mm, during the clinical course, in the absence of another cardiac or systemic disease capable of producing a similar magnitude of hypertrophy. Patients with known phenocopies of HCM (eg, Fabry disease, lysosomal associated membrane protein-2 cardiomyopathy, or amyloidosis) were excluded.
Paroxysmal AF
Paroxysmal AFs (PAFs) are episodes that terminate spontaneously or with intervention that restores sinus rhythm ≤7 days of onset and may recur with variable frequency. 4 AF episodes lasting >7 days and terminating spontaneously or with interventions (ie, persistent AF) are included within the PAF category for the purpose of the present data assembly and analysis.
Clinical Perspective
What Is New?
• In hypertrophic cardiomyopathy (HCM), timing and frequency of paroxysmal atrial fibrillation (AF) events are unpredictable, with an average 2-year interval between the first and second symptomatic episode, but progressing to permanent AF uncommonly. A substantial minority of patients (ie, 25%) have experienced only a single isolated paroxysmal AF episode.
• With current HCM management initiatives, AF is not an independent determinant of heart failure morbidity and is associated with low cardiovascular mortality with respect to heart failure, arrhythmic sudden death, or thromboembolism.
• Characterization of AF as inevitably progressive and a clinical turning point in the natural history of HCM is unjustified based on our cohort data.
• A low burden of paroxysmal AF (including only 1 episode) can be associated with the risk of thromboembolic events.
What Are the Clinical Implications?
• Although paroxysmal AF episodes are responsible for transient impairment in quality of life for many patients with HCM, AF burden can be reduced in a subset of patients by antiarrhythmic medications or catheter ablation but more substantially by the Maze procedure in symptomatic patients with left ventricular outflow obstruction undergoing surgical septal myectomy.
• AF is rarely the primary cause of death among patients with HCM, with the exception of thromboembolism in the absence of anticoagulation.
• Available scoring systems designed to predict stroke risk are unreliable in HCM, underscoring the importance of early prophylactic anticoagulation (usually after the first paroxysmal AF episode) in patients with HCM.
Permanent AF
Permanent AFs are episodes that persist until the patient and clinician make a shared decision together to cease further attempts to restore or maintain sinus rhythm, reflecting a therapeutic attitude toward AF in that patient rather than the inherent pathophysiology of the arrhythmia. 4 Long-standing persistent AF (continuous AF lasting >12 months in duration) was considered permanent AF.
Symptomatic Status
In this study, the functional status of patients with PAF was characterized by their symptoms occurring during periods of sinus rhythm and according to New York Heart Association (NYHA) functional classes. Notably, episodes of PAF are usually accompanied by symptoms of dyspnea, palpitations, and impaired consciousness, which are reversible when patients are returned to sinus rhythm either spontaneously or by interventions.
1,2,6-11
AF Management
Management strategies for AF, including anticoagulation, antiarrhythmic drug therapy, or AF catheter ablation or Maze procedure, are consistent with the 2003 American College of Cardiology/European Society of Cardiology and the 2011 American College of Cardiology/American Heart Association HCM management guidelines. 10, 12 Anticoagulation was recommended to each patient with ≥1 PAF episodes (or permanent AF) unless other contraindications were present. 10, 12 Antiarrhythmic medications, including amiodarone, disopyramide, sotalol, dofetilide, or dronedarone, were recommended based on a shared decision model taking into account risk and benefits of each medication. 4, 10, 12 AF catheter ablation was offered to patients with multiple symptomatic episodes of AF in whom antiarrhythmic drugs failed to control the frequency of AF or were not tolerated (or were declined), usually in patients who still regard their quality of life significantly impaired because of this arrhythmia. [26] [27] [28] [29] [30] [31] [32] [33] Initial catheter ablation consisted isolating of all pulmonary veins as confirmed with exit and entrance block. A repeat AF catheter ablation was offered to patients who still regarded their quality of life significantly impaired by recurrent symptomatic AF episodes uncontrolled by antiarrhythmic drugs after a first ablation procedure. Patients undergoing repeat ablation had isolation of any pulmonary veins that had regained conduction with selective use of supplemental lines, including left atrial roof lines and lines from the left inferior pulmonary vein to the mitral annulus with bidirectional block confirmed across all supplemental lines.
Biatrial Cox Maze procedures (Cox-Maze III or IV) with removal of the left atrial appendage were performed in patients with drug-refractory heart failure symptoms and a history of symptomatic AF at the time of surgical myectomy. 33, 34 In the vast majority of cases (n=69, 96%), the Cox-Maze IV procedure was performed using both bipolar radiofrequency and cryoablation. Bipolar radiofrequency ablation lesions were created around the bilateral pulmonary vein. After resection of the left atrial appendage, an ablation lesion was created between appendage and left pulmonary veins. The left atrial appendage was closed. A short posterior left atrial incision was made and a box lesion was performed between the right and left pulmonary veins by making connecting lesions between right and left pulmonary veins. A cryolesion was also delivered over the coronary sinus at the level of the P3 of mitral valve. Through left atriotomy, with the use of a cryoprobe, a connecting lesion was made: between the right pulmonary veins, the cryo-ice ball identified inside the left atrium, and P3 of the mitral valve. Left atriotomy was then closed. During rewarming, a right-sided Maze was performed by making a short vertical incision in the right atrium and placing a connecting lesion between the superior and inferior vena cavae. An isthmus lesion was placed between the right atriotomy and tricuspid annulus, and the right atriotomy was then closed.
The recurrence of AF after catheter ablation or Maze excluded a 3-month postprocedural blanking period.
Implantable Cardioverter-Defibrillators
Decisions to implant a primary prevention implantable cardioverter-defibrillator (ICD) in 136 patients were based on the presence of ≥1 conventional sudden death risk markers in accord with the 2011 US/Canada (American College of Cardiology/American Heart Association) management guidelines for HCM. 10 In 5 other patients, ICDs were placed for secondary prevention after resuscitation from out-of-hospital cardiac arrest.
Defibrillator discharges were considered appropriate when triggered by ventricular fibrillation or rapid ventricular tachycardia (rate >200 per minute) documented by stored electrograms or cycle length data. Interventions were inappropriate when triggered by heart rate exceeding the programmed threshold, such as with either supraventricular arrhythmias (including AF) or sinus tachycardia.
Imaging
Transthoracic echocardiographic studies were performed in the standard fashion. LV wall thickness was the maximal enddiastolic dimension within the chamber (usually ventricular septum). Other chamber dimensions, including LV end-diastolic and end-systolic and left atrial transverse dimension, were obtained as previously reported. 35 Continuous-wave Doppler was used to estimate the peak instantaneous LV outflow gradient. Outflow obstruction was defined as a gradient ≥30 mm Hg at rest or with physiological exercise on stress echocardiography. 36 Cardiovascular magnetic resonance studies were performed in 135 patients with a 1.5-T clinical scanner with cine sequences in standard views with full LV coverage. Late gadolinium enhancement images were acquired 10 to 15 minutes after intravenous administration of 0.2 mmol/ kg gadolinium-diethylene triamine pentaacetic acid using a breath-held segmented inversion-recovery sequence. Late gadolinium enhancement quantification was performed by manually adjusting the gray scale threshold to visually define areas of late gadolinium enhancement, which were summed and expressed as a proportion of total LV myocardium. 37 
Statistical Analyses
Descriptive Statistics
Survival and Event Analysis
For patients with known survival and event status, the fraction at each follow-up interval was estimated by the KaplanMeier method. Survival analysis end points were defined as all-cause and HCM-related mortality. Events that were analyzed by the Kaplan-Meier method included recurrent AF after initial episode or AF intervention, sudden death events, development of HF symptoms, and embolic events. Follow-up time for each patient was calculated from date of initial evaluation to most recent contact or event/death. A conditional logistic regression was performed to account for matched pairs. Patients who did not experience events at their most recent contact were censored in the analysis. Differences in survival or clinical events between patient groups were assessed using the log-rank test.
Survival analysis calculations of sudden death events excluded those patients with resuscitated cardiac arrest or an appropriate ICD intervention that occurred before initial clinical evaluation at our center. The analysis of heart failure progression excluded patients with advanced heart failure symptoms (NYHA class III or IV) that developed before initial clinical evaluation at our center, whereas analysis of anticoagulation excluded stroke events occurring before AF diagnosis. Statistical calculations were performed using SAS Enterprise Guide, version 7.1 (SAS Institute Inc).
RESULTS
Demographics
The 304 study patients with AF were 57±14 years of age (range, 16-89) at first evaluation and study entry, 62±13 years of age at the most recent assessment (or death), and 46±17 years of age at HCM diagnosis (Table 1, Figure 1 ); 205 patients (67%) were male. The first symptomatic AF event occurred at 54±14 years of age, including 14 (5%) <30 years of age, 90 (30%) at 30 to 50 years of age, and 44 (15%) at >70 years of age ( Figure 2) .
At initial evaluation, 191 patients (63%) were asymptomatic or mildly symptomatic while in sinus rhythm (ie, NYHA functional classes I or II), whereas the other 113 (37%) were in classes III or IV. At last evaluation, 246 patients (89%) were NYHA classes I or II. LV outflow obstruction was present at rest (gradient ≥30 mm Hg) in 108 patients (36%) or only after physiological exercise (gradient ≥30 mm Hg) in 62 others (20%).
At study entry, maximum LV wall thickness was 19±4 mm, with only 10 patients ≥30 mm (3%); transverse left atrial dimension was 46±7 mm (range 29-80), and greatly enlarged, ≥50 mm in 87 patients (29%) but normal (<40 mm) in 61 (20%). No correlation was discovered between left atrial dimension and age at AF onset (R 2 =0.003, P=0.36). Of the 304 patients, 135 (44%) had major interventions including surgical septal myectomy (n=100) or alcohol septal ablation (n=22) to relieve heart failure symptoms because of LV outflow obstruction, or heart transplant (n=16) for refractory heart failure in the absence of obstruction. Thirty-nine patients (13%) had associated atherosclerotic coronary artery disease with clinically relevant arterial stenosis; 88 (29%) had pharmacologically controlled systemic hypertension.
Paroxysmal AF
Two hundred twenty-six patients (74%) experienced ≥1 episodes of AF without evolution to permanent AF (range 1 to >20). The first event was at 54±15 years of age, with 14 patients ≤30 years of age. Periods of atrial flutter were also identified in 36 patients (16%).
Fifty-six patients experienced only a single isolated PAF episode over a period of 5.5±3.2 years and up to 16 years. One hundred seventy other patients had multiple PAF: 2 to 3 (n=84 patients), 4 to 5 (n=28 patients), 6 to 9 (n=16), and ≥10 (n=42); density was 0.8±0.8 PAFs per year. For the 170 patients with ≥2 episodes, the average time elapsed from the first to second episode was 2.2±3.2 years. Likelihood of a recurrent PAF episode at 5 years after initial AF occurrence was 67% (95% confidence interval, 61-74). No significant difference was found in left atrial dimension between the 56 patients with isolated PAF and the 170 patients with multiple episodes (45±7 versus 43±6, P=0.16).
Two hundred nine (of 226) patients survived to the end of follow-up; 188 were asymptomatic or mildly symptomatic in sinus rhythm in NYHA classes I or II at most recent evaluation, whereas 21 had advanced heart failure symptoms including 15 due to outflow obstruction. PAF patients were administered a variety of antiarrhythmic drugs to control the frequency of AF episodes at the discretion of their managing cardiologist, including most commonly beta-blockers (n=194), calcium channel blockers (n=91), amiodarone (n=84), or sotalol (n=57). Drugs administered for stroke prevention were predominantly warfarin in 128, but also direct oral anticoagulants in 59.
Permanent AF
Seventy-eight study patients (26%) were in permanent AF at 62±12 years of age, either at study entry (n=9) or evolved during follow-up (n=69). It is important to note that of the 78 patients with permanent AF, 52 (67%) had no or only mild symptoms at the end of follow-up. The 69 patients who evolved to permanent AF during follow-up had previously experienced PAF episodes 6.2±5.3 years earlier: 2 or 3 (n=28), 4 or 5 (n=9), or ≥6 (n=32). Patients with permanent AF had previously experienced a higher number of AF episodes than those who remained as patients with PAF (7±6 versus 5±5 episodes, P=0.003).
Cardioactive drugs were administered to achieve heart rate control (ie, basal rate <100/min), most commonly beta-blockers (n=67) or calcium channel blockers (n=46), and 9 patients underwent atrioventricularnodal ablation for this purpose. In an unsuccessful effort to restore sinus rhythm, 42 patients were treated with antiarrhythmic drugs (n=40) or catheter ablation/ Maze procedure (n=20). Drugs administered for stroke prevention were predominantly warfarin (n=64) but also direct oral anticoagulants (n=26).
Compared with patients with PAF, those with permanent AF were older at AF onset (57±12 versus 54±14, P=0.01); less commonly had LV outflow obstruction at rest (26% versus 39%, P=0.04) or underwent myectomy (21% versus 37%, P=0.01); and demonstrated lower ejection fraction (58±12 versus 63±7, P<0.001), larger left atrial dimension (49±7 versus 45±7, P<0.001), and larger LV end-diastolic cavity size (44±7 versus 42±7, P=0.01); and permanent AF was more frequently associated with end-stage heart failure (27% versus 7%, P<0.001) ( Table 1) .
Patients with permanent AF (or only PAF) did not differ with respect to NYHA functional class III/IV at last evaluation, risk for embolic stroke, or HCM-related and all-cause mortality. With multivariable analysis (Table I in the online-only Data Supplement), older age, larger left atrial dimension, and lower ejection fraction at initial evaluation were the only independent predictors for the development of permanent AF.
Thromboembolism
Of the 304 patients, 18 (6%) experienced thromboembolic strokes (of which 2 were ultimately fatal), including 11 in the PAF group and 7 in the permanent AF group. Ages were 61±15 years (range, .
Embolic strokes had a predilection for symptomatic patients with LV outflow obstruction (classes III/IV: 61% with stroke versus 36% without; gradients ≥30 mm Hg: 61% versus 34%; P=0.04 and P=0.01, respectively). However, occurrence of embolic strokes was unrelated to age at AF onset (P=0.13) or left atrial dimension (P=0.41), and on multivariable analysis no independent predictors for thromboembolic events were identified ( Table 2, Table II in the online-only Data Supplement).
Of the 18 stroke patients, 10 have not experienced residual neurological deficits. The other 8 patients incurred neurological impairment, which is considered mild, allowing functional independence, in 6 but associated with neurological disability in 2.
38 Four of the 18 stroke patients had been taking prophylactic anticoagulants (warfarin in 2, direct oral anticoagulants in 2), whereas 9 were untreated or noncompliant.
Embolic events were less common in patients taking anticoagulants (4/233, 2%) than in patients without anticoagulant prophylaxis (9/66, 14%, P<0.001). Thromboembolism occurred in association with first PAF episode in 5 patients and in the other 13 during either the second PAF (n=2), third to fifth (n=2), or after ≥5 episodes (n=9). The calculated CHA 2 DS 2 -VASc score was 0 or 1 in 8 patients (44%), indicative of a low estimated thromboembolic risk, and ≥2 in the remaining 10 patients (56%). Values are mean ± SD or n (%). ACE/ARB indicates angiotensin converting enzyme inhibitor or angiotensin receptor blocker; AF, atrial fibrillation; AV, atrioventricular; CAD, coronary artery disease; CMR, cardiovascular magnetic resonance; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LGE, late gadolinium enhancement; LVED, left ventricular enddiastolic dimension; LV, left ventricular; LVOT, left ventricular outflow tract; Max, maximum; NSVT, non-sustained ventricular tachycardia; NYHA-FC, New York Heart Association functional class; and SD, sudden death.
*Includes 6 patients with prior AF ablation. †Variable included in multivariable analysis. ‡Does not include 1 patient with unsuccessful alcohol ablation before surgical myectomy. §Includes 7 patients with prior myectomy and 1 with prior alcohol ablation. ¶ICD intervention occurred before development of permanent AF in 3 patients. ‖‖Three with subsequent appropriate ICD interventions 1 to 4 years after prior resuscitated cardiac arrests. **Including 9 postheart transplants. † †Including 7 postheart transplants. ‡ ‡In the 277 surviving patients. § §One procedure (n=30), 2 (n=15), 3 (n=4); 40 with radiofrequency ablation, 3 with cryoablation, and 6 with both radiofrequency and cryoablation, complications occurred in 7: sinus node dysfunction (n=1), pulmonary vein stenosis (after multiple ablations, n=1), hypotension and volume overload requiring vasopressors (n=4), VF arrest during the procedure (with successful defibrillation, n=1).
¶ ¶Includes 2 with prior embolic events. Drug-refractory unrelenting heart failure symptoms developed in 158 patients at some time during their clinical course. In 122 of these 158 patients, symptoms were judged to be attributable to LV outflow obstruction (gradients of 65±35 mm Hg), including 112 (92%) who ultimately achieved symptom relief with septal reduction to NYHA class I or II. The other 36 patients with advanced heart failure were nonobstructive, including 18 with systolic dysfunction because of end-stage remodeling and diffuse myocardial scarring; 6 of these patients had frequent symptomatic PAF (13±5 episodes) but also unrelenting heart failure symptoms while in sinus rhythm. Of the other 12 patients, advanced heart failure preceded permanent AF by 1 to 5 years in 6, whereas permanent AF preceded development of systolic dysfunction (by 2.2±1.7 years) in 6.
Eighteen other patients had advanced heart failure with preserved systolic function (EF ≥50%). Of these patients, 9 had frequent symptomatic PAF (11±7 episodes) but also unrelenting heart failure symptoms while in sinus rhythm. Of the other 9 patients, advanced heart failure preceded permanent AF by 2 to 5 years in 5, whereas permanent AF preceded development of advanced symptoms (by 7.5±8.3 years) in 4.
Acute Heart Failure Episodes
A distinct subset of 18 patients with PAF presented with acute heart failure decompensation, hypotension, and tachycardia (>100 beats/min), including 12 with a prior AF indicates atrial fibrillation; ASA, alcohol septal ablation; HCM, hypertrophic cardiomyopathy; HF, heart failure; NYHA-FC, New York Heart Association functional class; PAF, paroxysmal AF; and SD, sudden death. *In 3 patients, SD events occurred during an episode of PAF, although each also had 1 or 2 conventional risk markers. †In 3 patients, SD events occurred during an episode of PAF, although each also had 1 or 2 conventional risk markers, including 3 patients with a nonfatal SD event occurring before the development of permanent AF. ‡Of these 15 patients, 9 underwent transplant, 2 declined transplant, 2 were active on the transplant list, and 1 experienced HF death, including 2 patients with prior myectomy. §Of these 21 patients, 7 underwent transplant, 8 declined transplant, 3 experienced HF death, 2 experienced non-HCM deaths, and 1 was active on a transplant list. In 4 patients, AF was a potential contributor to the development of advanced HF, including 5 patients with prior myectomy and 1 with prior ASA. ǁSD in 2, HF death in 2, postoperative death in 2, and stroke-related death in 1. #HF death in 3 patients and stroke-related death in 1 patient. history of PAF. These patients required emergent treatment, including cardioversion to restore sinus rhythm, and supportive measures to normalize systemic perfusion, including 4 who were treated for cardiogenic shock.
These events comprised just 1.1% of the 1585 PAF episodes occurring in the cohort. Eight of the 18 patients progressed to surgical myectomy and Maze procedure (n=3), alcohol septal ablation (n=3), and heart transplant or listing (n=2). Notably, 15 patients have survived (12 in NYHA class I or II), whereas 3 died, including 1 with end-stage heart failure (8 years after the event) and 2 of noncardiac causes at 77 and 92 years of age.
Relationship Between AF and Sudden Death Events
Twenty-two patients had a history of both AF and a sudden death event, including 15 with appropriate ICD interventions, 5 resuscitated out-of-hospital cardiac arrests, and 2 sudden deaths. Of the 20 survivors, 17 were in permanent AF or sinus rhythm preceding ventricular tachycardia/ventricular fibrillation. However, 3 patients had ventricular tachycardia/ventricular fibrillation-mediated sudden death events while in PAF. These 3 patients represent just 1.3% of all 224 patients with PAF and comprise only 0.2% of the 1585 PAF episodes that occurred within the cohort.
Interventions for AF
AF Catheter Ablation
Seventy-two catheter ablations (ie, pulmonary vein isolation) were performed in 49 patients for recurrent symptomatic AF (1 to >20 PAF episodes). Over 4.4±4.2 years of follow-up, 15 of the 49 patients (31%) have not experienced additional symptomatic PAF episodes for up to 11 years whereas 34 (69%) have experienced ≥1 symptomatic PAF episode. Freedom from symptomatic AF recurrence after initial catheter ablation at 1 year was 44% (95% CI: 0.29, 0.58) and at 3 years was 32% (95% CI: 0.19, 0.47).
Repeat catheter ablations were performed in 19 patients for recurrent symptomatic AF, 2.0±2.8 years after the initial procedure, including 16 patients undergoing a single repeat ablation and 3 patients with 2 repeat ablations. Left atrial size was significantly larger in patients with AF recurrence after ablation than in patients without a recurrence (48±6 mm versus 42±7 mm, P=0.01). septal myectomy. Over 3.3±2.2 years of follow-up, 46 of these patients (64%) have not experienced additional symptomatic PAF episodes for up to 8 years whereas 26 (36%) have had ≥1 symptomatic PAF episode.
Maze Procedure
Freedom from symptomatic AF recurrence after Maze procedure at 1 year was 75% (95% CI: 0.63, 0.84) and at 3 years was 70% (95% CI: 0.56, 0.79) (Figure 3 ). Left atrial size was significantly larger in patients with AF recurrence than in patients without a recurrence (51±11 versus 46±7 mm, P=0.001).
Patients With Versus Without AF
Patients with AF were compared to those without a history of AF within the overall cohort. Specifically, no differences were evident between patients with versus without AF regarding sudden death event rate, allcause or HCM-related mortality (Figure 4 ), or progression of heart failure symptoms from class I/II to III/IV (freedom from progression at 5 years: 81% [95% CI: 74, 87] versus 80% [95% CI: 72, 87], P=0. 46) .
When this analysis was confined to patients with outflow obstruction, the rate of heart failure progression was also similar in patients with versus without AF (freedom from progression at 5 years: 69% [95% CI: 57, 78] versus 67% [95% CI: 53, 78], P=0.99) ( Figure 5 ).
When compared with respect to baseline clinical demographics (Table 3) , patients with a history of AF had larger left atrial dimensions (46±7 mm versus 41±6 mm, P<0.001), were more often in end-stage heart failure (11% versus 4%, P<0.001), had lower ejection fractions (62±9 versus 65±4, P<0.001), had larger LV enddiastolic dimensions (46±7 versus 41±6, P=0.02), and were younger at HCM diagnosis (47±17 versus 52±16). On multivariable analysis, the only independent predictors for development of AF were younger age at HCM diagnosis, larger left atrium, and lower ejection fraction (Table III in 
Outcome
Of the 304 study patients, 277 (91%) have survived over the follow-up period and 27 (9%) have died.
HCM-Related Mortality
In 11 patients (4% [0.7%/y]), death could be attributed to HCM at 64±9 years of age, including 5 because of advanced heart failure in the absence of LV outflow obstruction (Table 1) . Two patients died of embolic stroke at 61 and 62 years of age, 1 who had developed permanent AF and declined anticoagulation and the other in whom the event occurred at the time of the initial AF episode. HCM-related mortality rate did not differ between patients with AF onset <50 years of age and those ≥50 years of age (P=0.44).
Two patients died suddenly of HCM at 55 and 69 years of age, both in the absence of conventional sud- Values are mean ± SD or n (%). AF indicates atrial fibrillation; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverterdefibrillator; LV, left ventricular; LVED, left ventricular end-diastolic dimension; LVOT, left ventricular outflow tract; Max, maximum; NSVT, nonsustained ventricular tachycardia; NYHA-FC, New York Heart Association functional class.
*Included in multivariate analysis.
den death risk markers (10), with all PAF episodes preceding these events by >4 years. Two other patients died 9 or 19 days after myectomy. None of the 11 HCM patients who died had associated obstructive coronary artery disease based on angiography, clinical history of angina, prior myocardial infarction, or acute coronary event.
Non-HCM Mortality
Sixteen patients (5%) died of causes unrelated to HCM (1.1%/y) at 76±11 years of age (Table 1) . Eight deaths were because of multiple, largely noncardiac organ system failure, and neither HCM nor AF was judged to have importantly impacted demise. No significant difference was found in all-cause mortality between patients with PAF or permanent AF (1.5%/y versus 2.6%/y, P=0.23).
DISCUSSION
HCM is a genetic heart disease with heterogeneous clinical expression, outcome, and management optio ns. [1] [2] [3] [10] [11] [12] 35, 36, [39] [40] [41] Although absent in the majority of patients with HCM, symptomatic episodes of AF are now recognized as a common and important complication within the broad disease spectrum, sometimes poorly tolerated because of rapid ventricular rate and loss of the atrial contraction contribution to LV filling.
1,2,6-10 However, uncertainty remains regarding the impact of AF on the long-term clinical course of HCM. 6, 7, [15] [16] [17] [21] [22] [23] [24] Given the introduction of antiarrhythmic drugs and anticoagulants for the prevention of thromboembolic stroke, 1, 4, 10, [16] [17] [18] 20 as well as interventions such as AF catheter ablation with pulmonary vein isolation (and the Maze procedure) to obliterate the arrhythmic focus, [26] [27] [28] [29] [30] [31] [32] [33] [34] understanding the contemporary profile of AF in HCM has become particularly relevant. For these reasons, we have assessed the occurrence and consequences of AF in a large and well-defined single-institution cohort utilizing both group and individual patient profile analyses.
Several novel insights regarding the diverse expression and clinical significance of AF have emerged from interrogation of our consecutive HCM cohort. First, AF presenting as intermittent paroxysmal episodes predominated, showing substantial heterogeneity in frequency and timing. Timing of PAF events proved unpredictable, with an average 2-year interval between the first and second symptomatic episodes, and 25% had only a single PAF episode over a 5-year follow-up. Therefore, it is reasonable to defer consideration for antiarrhythmic therapy in most patients with HCM after an initial episode of AF.
However, ≈75% of patients had multiple episodes of PAF, significantly impacting quality of life, including some who elected (in collaboration with their managing cardiologist) to initiate antiarrhythmic drug therapy or undergo catheter ablation to reduce or eliminate these events. However, notably a substantial minority of patients (ie, 25%) have experienced only a single isolated PAF episode without recurrence over the followup period. Thereby, we found PAF to be unpredictable in timing and frequency, and uncommonly progressed to chronic AF. 6, 7, 15, [22] [23] [24] Second, HCM-related mortality associated with AF was low (0.7%/y) and did not differ from our patients with HCM without AF, or from that reported previ- ously in unselected HCM populations in the contemporary treatment era. 1, 3, 35 Notably, in only 2 HCM-related deaths could AF be incriminated as primarily responsible (ie, with both thromboembolic stroke events). One of these 2 deaths was potentially preventable, given that the patient was noncompliant with anticoagulation medications, but the other event occurred at initial presentation, obviating the possibility of prophylactic therapy.
Therefore, these data underscore the principle that the predominant mortality risk directly attributable to AF in HCM is the potential for thromboembolism, largely preventable by anticoagulation prophylaxis. 1, 6, 17, 18 Indeed, of those patients taking anticoagulant drugs, ≈2% incurred stroke events (either embolic or hemorrhagic, and nonfatal in each). Conversely, untreated or noncompliant patients had >7-fold more frequent thromboembolic events (ie, 14%), including the 1 stroke-related death.
Symptoms of progressive heart failure were the major source of morbidity in this study group. Although PAF often transiently impairs quality of life, our cohort analysis revealed limited evidence that AF is a direct cause or significant contributor to long-term heart failure deterioration for several reasons: (1) the rate at which advanced heart failure symptoms developed was no different in patients with or without a history of AF; (2) in most patients, advanced limiting symptoms actually preceded the onset of sporadic PAF episodes. 39, 41, 42 Nevertheless, in 10 patients (with either preserved or reduced ejection fraction), we could not exclude a contributing role for permanent AF because the arrhythmia preceded progression of heart failure by an average of 4 years. 6, 41 Furthermore, PAF only rarely led to acute heart failure and clinical decompensation (occurring in just 0.2% of all PAF episodes) and without conferring an increased risk for long-term HCM-mortality. Therefore, within the broad HCM disease spectrum, AF usually appears to represent a secondary event, a disease marker, or largely an innocent bystander to clinical events, rather than a primary cause.
Some previous reports have suggested that AF may also have a causative linkage to potentially lethal ventricular tachyarrhythmias and sudden death in HCM. 43, 44 However, in the present cohort, we found little evidence to support this association. First, patients with and without AF did not differ with respect to sudden death event rates. Second, the vast majority of ICD interventions to terminate ventricular tachycardia/ventricular fibrillation were immediately proceeded by periods of sinus rhythm. However, in 3 of the 224 patients with PAF, sudden death events occurred during the arrhythmic episode, although each of these patients also had 1 or 2 conventional risk markers.
Therefore, based on these data, AF could not be excluded as a contributing factor to ventricular tachycardia/ventricular fibrillation-mediated sudden death events in only 1% (3/304) of our study population. Overall, in our judgment, AF could have had a clinically relevant role in heart failure and sudden death events in only 2% of patients.
Predicting which patients with AF are prone to embolic events remains a challenging clinical dilemma in HCM. As previously suggested, 4, 6, 10, 12, 16 the prospective CHA 2 DS 2 -VASC score, designed to predict stroke risk in patients without HCM, proved unreliable in our HCM cohort, as evidenced by scores of 0 or 1 in almost 50% of the patients with embolic events who would therefore not have prospectively received a recommendation for prophylactic anticoagulation. Furthermore, in con- trast to previous analysis, 11, 16 we identified no clinical variables that could be used to either predict stroke events (including left atrial size) or reliably select patients for anticoagulant prophylaxis. 45, 46 Notably, 2 study patients not taking anticoagulants experienced embolic strokes after only 1 PAF episode (as well as 5 other patients during the first PAF). Therefore, in the absence of a reliable CHADs scoring system for HCM, we believe that these data support a low threshold for initiating life-long anticoagulation prophylaxis, probably most appropriate in most patients after the first symptomatic PAF episode independent of arrhythmia duration (or left atrial size) but also in accord with the principle of shared decision making and the lifestyle and personal wishes of the individual patient. It is important to note that although recent observations suggest that the prevalence of asymptomatic AF in HCM is significant, stroke rate and management of this issue in HCM is uncertain at this time. 25 PAF influenced quality of life in many patients, particularly when symptomatic episodes were frequent and required repetitive hospital visits to restore sinus rhythm, resulting in significant uncertainty, impairment in lifestyle, and loss of productivity, often triggering drug therapy and consideration for catheter ablation intervention. 1, 2, [6] [7] [8] [9] [10] 27 However, overall, morbidity in patients with PAF could not be considered substantial, with 90% incurring no or only mild functional limitation while in sinus rhythm, even including many patients permanently in AF.
In patients who elected AF catheter ablation (pulmonary vein isolation), 44% remained free of recurrent symptomatic AF over the first year and 32% at 3 years. Therefore, catheter ablation proved to be successful in only some of our patients with HCM. Recurrent AF after this procedure often required antiarrhythmic medications or repeat ablation. These results support our clinical practice of continuing anticoagulation indefinitely in all patients after AF catheter ablation.
In a separate subgroup of patients with a history of AF, the Maze procedure was performed at the time of surgical myectomy. Greater benefit achieved in these patients was evident by freedom from symptomatic AF after 1 year of 75%. The greater efficacy achieved by the Cox-Maze procedure could be related in part to the more extensive combined endocardial and epicardial ablation procedure compared with catheter ablation, as well as improved hemodynamics achieved by relief of outflow tract obstruction and reduction in left atrial pressure. 2, 33, 34, 47 Despite the demonstrated efficacy of the Maze procedure, our data do not specifically address a controversial management issue concerning the potential role of surgical myectomy performed earlier in patients with only mildly symptomatic obstructive HCM.
Therefore, based on this experience, combining myectomy with a Cox-Maze procedure has the potential to both effectively reverse heart failure symptoms and decrease AF burden. 1, 2, 10, 33, 34, 47 Our catheter ablation results are similar to those reported in other HCM populations, [26] [27] [28] [29] [30] [31] [32] although less effective than in general AF populations. 48 The more favorable data presented here for the Maze procedure is similar to that in the HCM series reported from Cleveland Clinic 34 or performed concomitantly with mitral valve replacement or coronary artery bypass grafting. 4 About 25% of our patients evolved to a permanent state of AF after an average of 7 paroxysmal episodes occurring over 6 years. Permanent AF has generally been considered a more advanced disease complication for patients with HCM, given the potentially adverse consequences attributed to chronic absence of atrial contraction and its contribution to LV filling. 6, 7, 15, 24 However, our data do not strongly support this view because most of our patients with permanent AF were in NYHA class I/II at the end of follow-up, and patients with permanent AF and PAF did not differ regarding the likelihood of embolic stroke or all-cause and HCMrelated mortality. Furthermore, only 25% of patients with a history of PAF ultimately developed permanent AF, mitigating the perception that AF in HCM is typically a progressive arrhythmia. 7, 15, [22] [23] [24] Overall morbidity and mortality evident in the present HCM AF cohort analysis differ from other recent surveys, which report more substantial adverse event rates (including stroke), attributable to AF, and conclude that this arrhythmia is an independent determinant of heart failure and all-cause and HCM-related mortality. 6, 7, [15] [16] [17] [18] [22] [23] [24] The Guttmann et al 22 and Siontis et al 15 data come from large multicenter or singleinstitution HCM populations accessed over long time periods, that cross therapeutic eras. Relying largely on group patient analysis, these studies report considerable mortality associated with or because of AF, manyfold greater than experienced by the patients in our study population. 15, 22 However, our single-institution study design has the advantage of using standardized diagnostic and management strategies for AF (ie, including extensive use of anticoagulation, antiarrhythmic medications, AF catheter ablation, and Maze procedure) during a contemporary time frame. This strategy allows detailed assessment of individual clinical profiles, recognizing that group statistical analysis in large populations may not allow full appreciation for the confounders that affect particular patients with AF.
In conclusion, AF is an important component of clinical course in many patients with HCM. Frequent PAF episodes although uncommon are responsible for transient impairment in many patients' quality of life. Clinical benefit in reducing PAF burden is now achievable in a subset of patients by catheter ablation and more substantially by the Maze procedure performed in highly symptomatic patients because of LV outflow obstruction. Nevertheless, despite the AF burden in HCM, this arrhythmia is associated with low cardiovascular mortality and does not appear to be an independent determinant of heart failure morbidity. AF is rarely the primary cause of death in HCM, with the exception of thromboembolism in the absence of anticoagulation, underscoring the importance of prophylactic therapy initiated with a low threshold, probably after the first symptomatic episode. Therefore, a characterization of AF as inevitably progressive and a clinical turning point in HCM would not appear entirely justified based on the cohort data assembled and reported here.
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